Bessemer Group
NBIX icon

Bessemer Group’s Neurocrine Biosciences NBIX Stock Holding History

Bessemer Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
2,941
+81
+3% +$12K ﹤0.01% 1170
2026
Q1 		$377K Sell
2,860
-38
-1% -$5.04K ﹤0.01% 1215
2025
Q4 		$411K Buy
2,898
+27
+0.9% +$3.91K ﹤0.01% 1194
2025
Q3 		$402K Buy
2,871
+95
+3% +$12.9K ﹤0.01% 928
2025
Q2 		$349K Sell
2,776
-3,984
-59% -$457K ﹤0.01% 945
2025
Q1 		$747K Sell
6,760
-13,893
-67% -$1.76M ﹤0.01% 780
2024
Q4 		$2.82M Sell
20,653
-1,113
-5% -$138K ﹤0.01% 583
2024
Q3 		$2.51M Buy
21,766
+20,168
+1,262% +$2.76M ﹤0.01% 612
2024
Q2 		$220K Hold
1,598
– – ﹤0.01% 990
2024
Q1 		$221K Sell
1,598
-8
-0.5% -$1.09K ﹤0.01% 999
2023
Q4 		$212K Buy
1,606
+56
+4% +$6.45K ﹤0.01% 1027
2023
Q3 		$175K Sell
1,550
-64
-4% -$6.74K ﹤0.01% 1061
2023
Q2 		$153K Buy
1,614
+130
+9% +$12.7K ﹤0.01% 1118
2023
Q1 		$150K Buy
1,484
+1,142
+334% +$119K ﹤0.01% 970
2022
Q4 		$42K Buy
342
+302
+755% +$35.4K ﹤0.01% 1180
2022
Q3 		$4K Sell
40
-11
-22% -$1.12K ﹤0.01% 1784
2022
Q2 		$5K Sell
51
-163
-76% -$15K ﹤0.01% 1527
2022
Q1 		$20K Buy
214
+4
+2% +$339 ﹤0.01% 1243
2021
Q4 		$18K Sell
210
-78
-27% -$7.17K ﹤0.01% 1294
2021
Q3 		$28K Buy
288
+125
+77% +$11.8K ﹤0.01% 1167
2021
Q2 		$16K Sell
163
-829
-84% -$79.5K ﹤0.01% 1267
2021
Q1 		$96K Buy
+992
New +$104K ﹤0.01% 888
2019
Q1 		– Sell
-155
Closed -$11K – 1896
2018
Q4 		$11K Hold
155
– – ﹤0.01% 1635
2018
Q3 		$19K Buy
+155
New +$17.6K ﹤0.01% 1476
2016
Q1 		– Sell
-149
Closed -$8K – 1600
2015
Q4 		$8K Buy
+149
New +$7.57K ﹤0.01% 1274
2015
Q1 		– Sell
-1,500
Closed -$34K – 1546
2014
Q4 		$34K Hold
1,500
– – ﹤0.01% 1010
2014
Q3 		$24K Buy
+1,500
New +$22.4K ﹤0.01% 990

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bessemer Group's NBIX Position: Q2 2026 in Review

Bessemer Group increased its Neurocrine Biosciences (NBIX) stake by 2.8% in Q2 2026, buying an estimated $12K and bringing the position to 2,941 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #1170.

Bessemer Group first reported a position in NBIX in Q3 2014 and has held it in 27 quarters since. The position peaked at $2.82M in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bessemer Group held 2,941 shares of Neurocrine Biosciences worth $496K as of Q2 2026.
  • Bessemer Group bought 81 Neurocrine Biosciences shares in Q2 2026, an estimated $12K.
  • Neurocrine Biosciences made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1170 holding.
  • Bessemer Group first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 27 quarters since.
  • Bessemer Group's Neurocrine Biosciences position peaked at $2.82M in Q4 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.